ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE

Organization Name

GENENTECH, INC.

Inventor(s)

Wei-Ching Liang of South San Francisco CA (US)

Joseph R. Arron of South San Francisco CA (US)

Daryle Depianto of South San Francisco CA (US)

Wendy Green Halpern of South San Francisco CA (US)

WeiYu Lin of South San Francisco CA (US)

Patrick J. Lupardus of South San Francisco CA (US)

Thirumalai Rajan Ramalingam of South San Francisco CA (US)

Dhaya Seshasayee of South San Francisco CA (US)

Tianhe Sun of South San Francisco CA (US)

Tulika Tyagi of South San Francisco CA (US)

Jia Wu of South San Francisco CA (US)

Yan Wu of South San Francisco CA (US)

Jian Ping Yin of South San Francisco CA (US)

ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18420510 titled 'ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE

The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.

Isoform-selective anti-TGFβ antibodies
Treatment of fibrosis and TGFβ-related disorders
Monoclonal antibodies targeting TGFβ2, TGFβ3, and TGFβ2/3
Potential therapeutic applications
Specific targeting of TGFβ isoforms

Potential Applications

The technology can be applied in the treatment of fibrosis, cancer, and other TGFβ-related disorders. It may also have applications in research settings for studying the role of TGFβ isoforms in various biological processes.

Problems Solved

The technology addresses the need for more precise and effective targeting of TGFβ isoforms in the treatment of diseases such as fibrosis. By selectively inhibiting specific isoforms, the antibodies offer a more tailored approach to therapy.

Benefits

The isoform-selective anti-TGFβ antibodies provide a more targeted and potentially less toxic treatment option for patients with fibrosis and other TGFβ-related conditions. This precision may lead to improved outcomes and reduced side effects compared to non-selective TGFβ inhibitors.

Commercial Applications

The technology has significant commercial potential in the pharmaceutical industry for the development of novel therapies targeting specific TGFβ isoforms. It may also attract interest from research institutions exploring the role of TGFβ in various diseases.

Questions about Isoform-Selective Anti-TGFβ Antibodies

What are the potential implications of using isoform-selective anti-TGFβ antibodies in cancer treatment?

Isoform-selective anti-TGFβ antibodies could offer a more targeted approach to cancer therapy by specifically inhibiting TGFβ isoforms involved in tumor progression. This may lead to more effective treatment strategies with fewer side effects.

How do isoform-selective anti-TGFβ antibodies differ from non-selective TGFβ inhibitors in terms of therapeutic efficacy?

Isoform-selective anti-TGFβ antibodies target specific isoforms of TGFβ, allowing for a more precise inhibition of the signaling pathways involved in disease progression. This targeted approach may result in improved therapeutic outcomes compared to non-selective inhibitors.

Original Abstract Submitted

The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.